Quick Answer
Fulcrum Therapeutics, Inc. reported Shares Outstanding of 66.58 million shares for fiscal year 2025.
Fulcrum Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 66.58M | +23.4% |
| 2024 | 53.97M | -12.8% |
| 2023 | 61.92M | +18.8% |
| 2022 | 52.10M | +28.2% |
| 2021 | 40.63M | +45.4% |
| 2020 | 27.94M | +23.3% |
| 2019 | 22.65M | +1326.6% |
| 2018 | 1.59M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 54.11M | +0.3% | +0.0% |
| June 30, 2025 | 54.09M | -13.1% | +0.2% |
| March 31, 2025 | 53.98M | -13.1% | +0.0% |
| December 31, 2024 | 53.97M | -12.8% | +0.1% |
| September 30, 2024 | 53.94M | +3.5% | -13.4% |
| June 30, 2024 | 62.25M | +19.5% | +0.2% |
| March 31, 2024 | 62.14M | +0.6% | +0.4% |
| December 31, 2023 | 61.92M | +18.8% | +18.8% |
- Fulcrum Therapeutics, Inc. showed an increase of +23.4% in Shares Outstanding compared to the prior fiscal year.
- Over the 2018–2025 period, Fulcrum Therapeutics, Inc.’s shares outstanding has grown by 4092.7% (from 1.59 million shares to 66.58 million shares).
- The most recent figure is from Fulcrum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: